Literature DB >> 6324579

Paraoxon hydrolysis in human serum mediated by a genetically variable arylesterase and albumin.

J Ortigoza-Ferado, R J Richter, S K Hornung, A G Motulsky, C E Furlong.   

Abstract

Gel filtration chromatography resolves human serum paraoxonase into two fractions: (1) a high molecular weight fraction that is completely inhibited by EDTA and coelutes with arylesterase (E.C.3.1.1.2); and (2) a second fraction that is closely associated with albumin, is only partially inhibited by EDTA, and has relatively little arylesterase activity under the assay conditions used. The activity of the high molecular weight fraction is stimulated by NaCl, whereas the albumin associated activity is partially inhibited by NaCl and is not present in serum derived from an analbuminemic individual. Our data suggest that albumin itself, rather than a protein bound to or cofractionating with albumin, mediates paraoxonase activity. The variation in levels of the activity of the nonalbumin, high molecular weight enzyme is responsible for the observed polymorphism of paraoxonase activity in human serum or plasma. An optimal assay of polymorphic paraoxonase activity should be based on activity measurements of the nonalbumin fraction. It is considered likely that only the nonalbumin fraction is responsible for in vivo hydrolysis of paraoxon.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6324579      PMCID: PMC1684442     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  18 in total

1.  Genetic polymorphism and interethnic variability of plasma paroxonase activity.

Authors:  J R Playfer; L C Eze; M F Bullen; D A Evans
Journal:  J Med Genet       Date:  1976-10       Impact factor: 6.318

2.  Organophosphate splitting serum enzymes in different mammals.

Authors:  R Zech; K Zürcher
Journal:  Comp Biochem Physiol B       Date:  1974-07-15

3.  Effects of lipid removal on the molecular size and kinetic properties of bovine plasma arylesterase.

Authors:  B J Kitchen; C J Masters; D J Winzor
Journal:  Biochem J       Date:  1973-09       Impact factor: 3.857

4.  [Genetically determined polymorphism of human serum paraoxonase (EC 3.1.1.2)].

Authors:  H H Lindorf; M Petenyi; M Flügel; T Fischer; T Hiller
Journal:  Humangenetik       Date:  1973

5.  [Letter: Comments in response to genetically determined polymorphism of human serum paraxonase (EC 3.1.1.2) (author's transl)].

Authors:  H H Lindorf; M Petenyi; M Flügel; T Fischer; T Hiller
Journal:  Humangenetik       Date:  1973-09-20

6.  [Enzymatic hydrolysis of diethyl-p-nitrophenylphosphate (E 600) by human serum].

Authors:  K Krisch
Journal:  Z Klin Chem Klin Biochem       Date:  1968-01

7.  [Differences in the reaction of human serum cholinesterases with E 600 (0,0-diethyl-0-(p-nitrophenyl)-phosphate)].

Authors:  U Rabast; H H Lindorf
Journal:  Arch Toxikol       Date:  1969

8.  Evaluation of a cellulose-acetate electrophoresis system for serum protein fractionation.

Authors:  A Kaplan; J Savory
Journal:  Clin Chem       Date:  1965-10       Impact factor: 8.327

9.  Analbuminemia in an American Indian girl.

Authors:  H Boman; M Hermodson; C A Hammond; A G Motulsky
Journal:  Clin Genet       Date:  1976-05       Impact factor: 4.438

10.  On the genetics of the human serum paraoxonase (EC 3.1.1.2).

Authors:  M Geldmacher-v Mallinckrodt; G Hommel; J Dumbach
Journal:  Hum Genet       Date:  1979-09       Impact factor: 4.132

View more
  16 in total

Review 1.  Human PON1, a biomarker of risk of disease and exposure.

Authors:  C E Furlong; S M Suzuki; R C Stevens; J Marsillach; R J Richter; G P Jarvik; H Checkoway; A Samii; L G Costa; A Griffith; J W Roberts; D Yearout; C P Zabetian
Journal:  Chem Biol Interact       Date:  2010-03-23       Impact factor: 5.192

2.  Investigation of an albumin-enriched fraction of human serum and its albuminome.

Authors:  Rebekah L Gundry; Qin Fu; Christine A Jelinek; Jennifer E Van Eyk; Robert J Cotter
Journal:  Proteomics Clin Appl       Date:  2007-01-01       Impact factor: 3.494

3.  Paraoxonase-1 and clopidogrel efficacy.

Authors:  Jordi Camps; Jorge Joven; Bharti Mackness; Michael Mackness; Dan Tawfik; Dragomir Draganov; Lucio G Costa; György Paragh; Ildikó Seres; Sven Horke; Richard James; Antonio Hernández; Srinivasa Reddy; Diana Shih; Mohamed Navab; Daniel Rochu; Michael Aviram
Journal:  Nat Med       Date:  2011-09-07       Impact factor: 53.440

Review 4.  The human serum paraoxonase/arylesterase polymorphism.

Authors:  B N La Du
Journal:  Am J Hum Genet       Date:  1988-09       Impact factor: 11.025

5.  Paraoxonases-1, -2 and -3: What are their functions?

Authors:  Clement E Furlong; Judit Marsillach; Gail P Jarvik; Lucio G Costa
Journal:  Chem Biol Interact       Date:  2016-05-26       Impact factor: 5.192

Review 6.  Paraoxonase-1 and Early-Life Environmental Exposures.

Authors:  Judit Marsillach; Lucio G Costa; Clement E Furlong
Journal:  Ann Glob Health       Date:  2016 Jan-Feb       Impact factor: 2.462

Review 7.  Pharmacogenetics and ecogenetics.

Authors:  D P Agarwal; H W Goedde
Journal:  Experientia       Date:  1986-10-15

8.  Detection of adduct on tyrosine 411 of albumin in humans poisoned by dichlorvos.

Authors:  Bin Li; Ivan Ricordel; Lawrence M Schopfer; Frédéric Baud; Bruno Mégarbane; Florian Nachon; Patrick Masson; Oksana Lockridge
Journal:  Toxicol Sci       Date:  2010-04-15       Impact factor: 4.849

9.  Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry assay for organophosphorus toxicants bound to human albumin at Tyr411.

Authors:  Bin Li; Lawrence M Schopfer; Steven H Hinrichs; Patrick Masson; Oksana Lockridge
Journal:  Anal Biochem       Date:  2006-12-04       Impact factor: 3.365

10.  Paraoxonase 1 (PON1) status and substrate hydrolysis.

Authors:  Rebecca J Richter; Gail P Jarvik; Clement E Furlong
Journal:  Toxicol Appl Pharmacol       Date:  2008-11-13       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.